Cargando…
Cross-Protective IgG and IgA Antibodies against Oncogenic and Non-Oncogenic HPV Genotypes
OBJECTIVE: The aim of the study was to describe the course of IgG/IgA immune response in women immunized with bivalent vaccine and in women non-vaccinated with HPV infection, as well as evaluating the cross-protection against non-vaccine HPV types. METHODS: Serum and cervical mucus samples were coll...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
West Asia Organization for Cancer Prevention
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779425/ https://www.ncbi.nlm.nih.gov/pubmed/32986383 http://dx.doi.org/10.31557/APJCP.2020.21.9.2799 |
_version_ | 1783631331072147456 |
---|---|
author | Costa, Ana Paula Giraldo, Paulo César Cobucci, Ricardo Ney Consolaro, Márcia Lopes Souza, Raquel Pantarotto Canário, Luanda Barbara Machado, Paula Renata Martins, Rand Randall Baptista, Pedro Vieira Jr, José Eleutério Gonçalves, Ana Katherine |
author_facet | Costa, Ana Paula Giraldo, Paulo César Cobucci, Ricardo Ney Consolaro, Márcia Lopes Souza, Raquel Pantarotto Canário, Luanda Barbara Machado, Paula Renata Martins, Rand Randall Baptista, Pedro Vieira Jr, José Eleutério Gonçalves, Ana Katherine |
author_sort | Costa, Ana Paula |
collection | PubMed |
description | OBJECTIVE: The aim of the study was to describe the course of IgG/IgA immune response in women immunized with bivalent vaccine and in women non-vaccinated with HPV infection, as well as evaluating the cross-protection against non-vaccine HPV types. METHODS: Serum and cervical mucus samples were collected from infected and vaccinated women for HPV detection/genotyping and for detection of IgG/IgA anti-HPV/VLP (Virus-like Particles) by ELISA. RESULTS: The median absorbance detected in serum samples for anti-HPV-IgG antibodies was higher in vaccinated women when compared to HPV infected women (p <0.01), however, the median absorbance in cervical mucus samples for anti-HPV-IgA was higher in infected women when compared to vaccinated women (p<0.01). Additionally, our analyses also provided additional evidence for cross-protective efficacy of the HPV-16/18 vaccine against HPV-82, -6, -11, -13, -61, -72 and -74. CONCLUSION: The IgG antibodies were significantly more detected in the serum of vaccinated women, while the IgA was found in greater quantities in cervical samples from those infected by the virus. In addition, there is evidence that the bivalent vaccine provides cross-protection against other non-oncogenic viral subtypes. |
format | Online Article Text |
id | pubmed-7779425 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | West Asia Organization for Cancer Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-77794252021-01-08 Cross-Protective IgG and IgA Antibodies against Oncogenic and Non-Oncogenic HPV Genotypes Costa, Ana Paula Giraldo, Paulo César Cobucci, Ricardo Ney Consolaro, Márcia Lopes Souza, Raquel Pantarotto Canário, Luanda Barbara Machado, Paula Renata Martins, Rand Randall Baptista, Pedro Vieira Jr, José Eleutério Gonçalves, Ana Katherine Asian Pac J Cancer Prev Research Article OBJECTIVE: The aim of the study was to describe the course of IgG/IgA immune response in women immunized with bivalent vaccine and in women non-vaccinated with HPV infection, as well as evaluating the cross-protection against non-vaccine HPV types. METHODS: Serum and cervical mucus samples were collected from infected and vaccinated women for HPV detection/genotyping and for detection of IgG/IgA anti-HPV/VLP (Virus-like Particles) by ELISA. RESULTS: The median absorbance detected in serum samples for anti-HPV-IgG antibodies was higher in vaccinated women when compared to HPV infected women (p <0.01), however, the median absorbance in cervical mucus samples for anti-HPV-IgA was higher in infected women when compared to vaccinated women (p<0.01). Additionally, our analyses also provided additional evidence for cross-protective efficacy of the HPV-16/18 vaccine against HPV-82, -6, -11, -13, -61, -72 and -74. CONCLUSION: The IgG antibodies were significantly more detected in the serum of vaccinated women, while the IgA was found in greater quantities in cervical samples from those infected by the virus. In addition, there is evidence that the bivalent vaccine provides cross-protection against other non-oncogenic viral subtypes. West Asia Organization for Cancer Prevention 2020-09 /pmc/articles/PMC7779425/ /pubmed/32986383 http://dx.doi.org/10.31557/APJCP.2020.21.9.2799 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Costa, Ana Paula Giraldo, Paulo César Cobucci, Ricardo Ney Consolaro, Márcia Lopes Souza, Raquel Pantarotto Canário, Luanda Barbara Machado, Paula Renata Martins, Rand Randall Baptista, Pedro Vieira Jr, José Eleutério Gonçalves, Ana Katherine Cross-Protective IgG and IgA Antibodies against Oncogenic and Non-Oncogenic HPV Genotypes |
title | Cross-Protective IgG and IgA Antibodies against Oncogenic and Non-Oncogenic HPV Genotypes |
title_full | Cross-Protective IgG and IgA Antibodies against Oncogenic and Non-Oncogenic HPV Genotypes |
title_fullStr | Cross-Protective IgG and IgA Antibodies against Oncogenic and Non-Oncogenic HPV Genotypes |
title_full_unstemmed | Cross-Protective IgG and IgA Antibodies against Oncogenic and Non-Oncogenic HPV Genotypes |
title_short | Cross-Protective IgG and IgA Antibodies against Oncogenic and Non-Oncogenic HPV Genotypes |
title_sort | cross-protective igg and iga antibodies against oncogenic and non-oncogenic hpv genotypes |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779425/ https://www.ncbi.nlm.nih.gov/pubmed/32986383 http://dx.doi.org/10.31557/APJCP.2020.21.9.2799 |
work_keys_str_mv | AT costaanapaula crossprotectiveiggandigaantibodiesagainstoncogenicandnononcogenichpvgenotypes AT giraldopaulocesar crossprotectiveiggandigaantibodiesagainstoncogenicandnononcogenichpvgenotypes AT cobucciricardoney crossprotectiveiggandigaantibodiesagainstoncogenicandnononcogenichpvgenotypes AT consolaromarcialopes crossprotectiveiggandigaantibodiesagainstoncogenicandnononcogenichpvgenotypes AT souzaraquelpantarotto crossprotectiveiggandigaantibodiesagainstoncogenicandnononcogenichpvgenotypes AT canarioluandabarbara crossprotectiveiggandigaantibodiesagainstoncogenicandnononcogenichpvgenotypes AT machadopaularenata crossprotectiveiggandigaantibodiesagainstoncogenicandnononcogenichpvgenotypes AT martinsrandrandall crossprotectiveiggandigaantibodiesagainstoncogenicandnononcogenichpvgenotypes AT baptistapedrovieira crossprotectiveiggandigaantibodiesagainstoncogenicandnononcogenichpvgenotypes AT jrjoseeleuterio crossprotectiveiggandigaantibodiesagainstoncogenicandnononcogenichpvgenotypes AT goncalvesanakatherine crossprotectiveiggandigaantibodiesagainstoncogenicandnononcogenichpvgenotypes |